Osteoporosis Update: Personalized Risk Assessment and Treatment
Обновление по остеопорозу: персонализированная оценка риска и лечение
2026-02-16
SCID: 54.1/525nq5hd
Discuss with AI
osteoporosispostmenopausal women hip fracture inpatient useromosozumab cardiovascular safetytrabecular bone scorezoledronate underuse
Figures from the paper
Abstract (AI)
The clinical update offers a concise overview of recently published, high-impact journal articles that may influence clinical practice, summarized for our readers. This edition highlights recent studies related to the diagnosis and management of osteoporosis. It reviews essential international guidelines on the clinical use of trabecular bone score (TBS) and a goal-oriented approach to treatment, alongside emerging data on the cardiovascular safety of romosozumab and evidence underscoring the underuse of zoledronate. In particular, it discusses the limited utilization of zoledronate in early postmenopausal women and its inpatient use in older adults after hip fractures.
Key Findings
1
Emerging data assess the cardiovascular safety profile of romosozumab.
2
Evidence indicates zoledronate is underused, particularly in early postmenopausal women.
3
International guidelines on clinical use of trabecular bone score (TBS) and a goal-oriented treatment approach are emphasized.
4
Recent high-impact studies may influence osteoporosis clinical practice by updating diagnosis and management approaches.
5
Zoledronate is often used inpatient for older adults after hip fractures, highlighting differential utilization by setting and age.
Research Object
Osteoporosis diagnosis and management in clinical practice
Research Subject
Personalized risk assessment and treatment strategies including use of trabecular bone score (TBS), goal-oriented therapy, cardiovascular safety of romosozumab, and utilization patterns of zoledronate
Publication Details
Publication Date
2026-02-16
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Download PDF
Subscribe to digest